Such as the combination of paclitaxel targeted BCL2 and lapatinib targeted EGFR was reported to be effective for HER2 + breast cancer in the clinical trial phase 3 (Liu Y. et al., 2014). This evidence concerns the gene EGFR and breast cancer.